Women who have used Fosamax are nearly twice as likely to develop atrial fibrillation (quivering of your heart’s upper chambers), which is the most common kind of chronically irregular heartbeat.
Fosamax is the most widely used drug treatment for the bone-thinning disease osteoporosis. The FDA approved the first generic version (called alendronate) in February.
The drug was associated with an 86 percent higher risk of atrial fibrillation compared with never having used the drug. Atrial fibrillation can cause palpitations, fainting, fatigue, or congestive heart failure. They can also lead to embolic strokes.